GET DAILY SIGNALS$PFE Swing Trader: Strong performance from Deep TA & Trend Analysis
Deep Trend Analysis (TA) Generates 5.49% for Pfizer (PFE) with Swing Trading
Swing trading is a renowned strategy used by countless investors worldwide. It is a short-term trading method that aims to capture gains within a span of days or weeks, leveraging the technical analysis of a company's stocks. A compelling instance of this is the deep trend analysis (TA) generating a strong performance on Pfizer Inc. (PFE).
The application of the Relative Strength Index (RSI) - a critical technical indicator for swing traders, was instrumental in this case. RSI measures the speed and change of price movements, often used to identify overbought or oversold conditions in a market. For PFE, the RSI indicator was seen ascending from the oversold territory.
An oversold condition is typically a signal that the market has been heavily bearish for a period, pushing prices down to extremely low levels. When the RSI ascends from this territory, it implies a potential trend reversal, offering an optimal moment for traders to step in. In the case of PFE, traders who recognized this shift and made timely trades would have benefited from a substantial 5.49% gain.
Beyond its application in identifying potential market reversals, RSI is also efficient at recognizing general market trends. In the context of PFE, the RSI's upward movement from the oversold territory also illustrated a broader upward price trend. It served as a definitive testament to the value of deep trend analysis, underlining the power of technical indicators in swing trading.
While the technical indicators and analysis methods are essential tools for any swing trader, it's equally important to understand the context behind these movements. Pfizer, a leading global pharmaceutical company, has been at the forefront of medical breakthroughs and developments. The deep trend analysis for PFE aligns with the company's strong performance, contributing to its advantageous position in the market.
The strong performance from swing trading in PFE is a clear testament to the significance and potential of technical analysis in successful short-term trading strategies. This profitable venture reaffirms that with vigilant monitoring, accurate interpretations, and timely decisions, swing trading can indeed be a fruitful exercise for investors.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
PFE sees MACD Histogram just turned negative
PFE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 25 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 57%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 13 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 58 cases where PFE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In 47 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Bullish Trend Analysis
Following a +2.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 152 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 86 of 193 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 45%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 26 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.966) is normal, around the industry mean (-1.421). P/E Ratio (38.169) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.059) settles around the average of (0.038) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor
Advertisement